News Headlines

31. Fujifilm Rebrands Life Sciences Companies To Strengthen Position As Strategic Partners For Life, Offering End-To-End Solutions 6/2/2025

    FUJIFILM Corporation's Life Sciences Group companies, a portfolio of businesses offering products, services and comprehensive solutions that span all stages of therapeutic development from discovery through to commercialization, today announced new names and identities as part of a strategic positioning effort.

32. Made Scientific Powers Late-Phase And Commercial Cell Therapy Manufacturing With 12,000 sq. ft. Expansion In Princeton, NJ GMP Facility 5/29/2025

    Made Scientific, a leading cell therapy contract development and manufacturing organization (CDMO), today announced a significant expansion of its Princeton, New Jersey facility to meet increasing demand from late-phase and commercial clients and support the anticipated rise in approved advanced therapies.

33. Cellares And Mitsui Fudosan Announce The First IDMO Smart Factory For Commercial-Scale Cell Therapy Manufacturing In Japan 5/29/2025

    Cellares, a pioneer in automated cell therapy manufacturing, in collaboration with Mitsui Fudosan, announces the establishment of Japan’s first next-gen commercial production site for CAR-T cell therapies.

34. Bora Adds Automated Fill/Finish Line In Baltimore 5/29/2025

    Bora Pharmaceuticals Co., Ltd., a global leader in pharmaceutical manufacturing, today announced that due to continued growth in demand for its drug product services, it plans to add further sterile fill/finish capacity at its facility in Baltimore, Maryland.

35. Bionique Testing Laboratories And Cellipont Bioservices Partner To Accelerate Adoption Of Rapid Mycoplasma Testing In Cell And Gene Therapy Manufacturing 5/29/2025

    Bionique Testing Laboratories, a global leader in mycoplasma testing services and part of the Asahi Kasei group, and Cellipont Bioservices, a premier Contract Development and Manufacturing Organization (CDMO) specializing in cell therapies, announce a strategic partnership to advance the adoption and validation of rapid mycoplasma detection methods in support of cGMP manufacturing for cell and gene therapies.

36. Radyus Research And Eurofins CDMO Alphora Announce Strategic Partnership To Accelerate And Optimize Drug Development 5/28/2025

    Radyus Research, a U.S.-based drug development organization, and Eurofins CDMO Alphora, a Canadian contract development and manufacturing organization announced a new strategic partnership to help accelerate early-stage drug development for biotech companies worldwide.

37. BrainStorm Secures Key Manufacturing Partnership With Minaris For Upcoming NurOwn™ Phase 3b ALS Clinical Trials 5/27/2025

    BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has signed a Letter of Intent (LOI) with Minaris Advanced Therapies, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, to manufacture NurOwn® for its upcoming clinical trial.

38. Lilly To Expand Its Pain Pipeline With Acquisition Of SiteOne Therapeutics 5/27/2025

    Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ("SiteOne"), a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, today announced a definitive agreement for Lilly to acquire SiteOne.

39. Bachem Expands Multi-Site Production Capacities To Meet Rising Demand 5/27/2025

    Bachem has announced major investment across their site network, with new funding to improve production facilities at their Bubendorf, Vista and St Helens sites, along with a new site in Sisseln.

40. Onco-Innovations Announces Start Of Manufacturing Of Preclinical Testing Material For Its PNKP Inhibitor Technology By Dalton Pharma 5/26/2025

    Onco-Innovations Limited ("Onco" or the "Company") is pleased to announce that Dalton Pharma Services ("Dalton") has commenced activities to manufacture material for preclinical testing of the Company's exclusively-licensed nanoparticle-formulated Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitor technology.